Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amarin Corp ADR
(NQ:
AMRN
)
0.6286
+0.0136 (+2.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amarin Corp ADR
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
August 22, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Plc (AMRN) Q2 2024 Earnings Call Transcript
July 31, 2024
AMRN earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
July 31, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
3 Breakthrough Stocks Under $10 Set for Massive Upside
July 29, 2024
Discover the top breakthrough stocks under $10 with strong fundamentals and strategic advantages to hit massive upside.
Via
InvestorPlace
Earnings Scheduled For February 29, 2024
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
July 17, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
July 17, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
July 08, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
July 05, 2024
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides.
Via
Investor's Business Daily
Why Core & Main Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
June 04, 2024
Via
Benzinga
Amarin Board of Directors Announces CEO Transition
June 04, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
May 28, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 06, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
AMRN Stock Earnings: Amarin Corp Beats EPS, Misses Revenue for Q1 2024
May 01, 2024
AMRN stock results show that Amarin Corp beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Amarin Plc (AMRN) Q1 2024 Earnings Call Transcript
May 01, 2024
AMRN earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Amarin Reports First Quarter 2024 Business Update and Financial Results
May 01, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 24, 2024
Via
Benzinga
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
April 24, 2024
Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect Patients
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Announces Results of Annual General Meeting of Shareholders
April 22, 2024
- Shareholders Approve Share Repurchase Program of up to $50 Million -
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
April 15, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
April 08, 2024
Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action
From
Amarin Corporation plc
Via
GlobeNewswire
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
April 06, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Why Amarin Stock Was Rocketing Higher on Wednesday
April 03, 2024
There was unambigously good news about the company's single commercialized medication.
Via
The Motley Fool
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
April 03, 2024
Company’s IP Protection for VAZKEPA® in Europe Now Extended Into 2039
From
Amarin Corporation plc
Via
GlobeNewswire
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
March 25, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript
February 29, 2024
AMRN earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why Is Amarin Stock Trading Lower After Q4 Earnings?
February 29, 2024
Amarin's Q4 2023 financials: Revenues at $74.71 million, beating consensus. US net product revenue is $64.9 million, down Y/Y. CEO Patrick Holt shares operational progress, including European market...
Via
Benzinga
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 29, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 29, 2024
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.
Via
Benzinga
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
February 15, 2024
From
Amarin Corporation plc
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.